GleamWall
中文EN

ICCC IMMUCELL CORP /DE/

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 811641 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY19.6%
TTM net income YoY-19.1%
TTM EPS YoY-32.1%
Revenue 3-yr CAGR26.8%
Net income 3-yr CAGR—

Margins

Gross margin40.8%
Operating margin14.5%
Net margin5.7%
FCF margin16.3%
EBITDA margin21.0%

Returns

ROE6.0%
ROA4.2%
ROIC (approx.)13.8%
Asset turnover0.73x

Leverage & solvency

Liabilities / assets31.7%
Debt / equity0.24x
Current ratio4.61x
Interest coverage12.19x

Cash quality & payout

Operating cash flow / net income4.17x
Accruals ratio-13.2%
Payout ratio—
Capex / revenue7.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$8.04M$7.19M$10.36M$7.63M$5.51M$6.44M$8.07M$7.75M
Cost of revenue$4.48M$4.75M$5.70M$4.72M$3.14M$3.63M$4.71M$4.92M
Gross profit$3.56M$2.44M$4.66M$2.91M$2.36M$2.82M$3.35M$2.83M
R&D expense$176,771$119,652$317,688$758,864$694,311$831,858$756,847$819,393
SG&A expense$1.29M$1.27M$1.14M$1.13M$729,421$720,418$622,843$554,711
Operating income$957,770$1.93M$1.97M-$57,956$20,075$569,562$1.12M$621,395
Interest expense$92,527$95,667$99,675$106,145$134,516$124,795$127,928$136,196
Pretax income$935,275$1.88M$1.95M-$2.85M-$135,292$503,784$1.45M$520,591
Income tax-$17,235$45,950$12,522$3,306$4,456$1,904$1,904$6,036
Net income$952,510$1.83M$1.94M-$2.85M-$139,748$501,880$1.45M$514,555
EBITDA$1.42M$2.41M$2.50M$651,516$728,742$1.25M$1.80M$1.31M
EPS (basic)0.100.200.21—-0.020.060.16—
EPS (diluted)0.100.200.21—-0.020.060.16—
Weighted avg. shares (diluted)9.30M9.19M9.05M—9.05M9.03M8.98M—
Balance sheet
Cash & equivalents$7.91M$8.86M$6.81M$3.81M$3.89M$6.00M$4.60M$3.76M
Receivables$3.37M$2.90M$2.69M$3.42M$2.55M$2.38M$3.35M$3.77M
Inventory$9.86M$9.08M$8.67M$9.27M$9.80M$8.29M$7.36M$7.11M
Current assets$21.58M$21.08M$18.86M$16.94M$16.83M$17.14M$15.92M$15.04M
PP&E, net$21.92M$21.03M$20.78M$21.07M$24.34M$24.88M$25.02M$25.35M
Goodwill$95,557$95,557$95,557$95,557$95,557$95,557$95,557$95,557
Intangibles———$0$4,776$9,552$14,328$19,104
Total assets$47.96M$46.63M$44.11M$42.53M$42.53M$42.53M$45.62M$45.10M
Current liabilities$4.68M$4.44M$3.91M$3.98M$4.00M$4.45M$3.87M$4.41M
Short-term debt$1.38M$1.51M$1.63M$1.61M$1.59M$1.54M$1.52M$1.50M
Long-term debt$6.52M$6.80M$7.07M$7.49M$7.90M$8.26M$8.65M$9.04M
Total debt$7.90M$8.30M$8.70M$9.10M$9.49M$9.80M$10.17M$10.54M
Total liabilities$15.18M$15.26M$14.97M$15.48M$15.93M$16.85M$16.63M$17.58M
Shareholders' equity$32.77M$31.37M$29.14M$27.06M$29.80M$29.87M$28.99M$27.52M
Net debt-$15,557-$557,319$1.89M$5.29M$5.60M$3.80M$5.57M$6.78M
Shares outstanding9.09M9.08M9.05M9.05M9.05M9.05M8.98M8.98M
Cash flow statement
Operating cash flow$755,906$3.02M$3.57M$482,541-$1.18M$1.60M$1.57M-$3,051
Capital expenditure$1.35M$733,939$177,230$172,306$593,924$155,159$329,050$196,216
Free cash flow-$589,355$2.29M$3.40M$310,235-$1.78M$1.45M$1.24M-$199,267
Investing cash flow-$1.35M-$733,939-$167,230-$167,306-$592,024-$125,927-$329,050-$196,216
Financing cash flow-$356,444-$237,564-$399,995-$394,602-$337,689-$76,448-$403,647$148,866
Depreciation & amortization$459,357$470,621$531,452$709,472$708,667$679,037$686,773$684,655
Stock-based compensation$396,457$239,867$137,949$103,781$73,161$66,714$52,215$68,863

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.